journal article·2024-09Open access

Metal‐Coordinated NIR‐II Nanoadjuvants with Nanobody Conjugation for Potentiating Immunotherapy by Tumor Metabolism Reprogramming

Yeneng Dai, Ziang Guo, Dongliang Leng, Guanda Jiao, Kai Chen, Mingxuan Fu, Yang Liu, Qingming Shen, Qi Wang, Lipeng Zhu, Qi Zhao

Advanced Science· Volume 11· Issue 34

Abstract

Abstract Immune checkpoint blockade (ICB) immunotherapy remains hampered by insufficient immunogenicity and a high‐lactate immunosuppressive tumor microenvironment (TME). Herein, a nanobody‐engineered NIR‐II nanoadjuvant with targeting metabolic reprogramming capability is constructed for potentiating NIR‐II photothermal‐ferroptosis immunotherapy. Specifically, the nanoadjuvant (2DG@FS‐Nb) is prepared by metallic iron ion‐mediated coordination self‐assembly of D‐A‐D type NIR‐II molecules and loading of glycolysis inhibitor, 2‐deoxy‐D‐glucose (2DG), followed by modification with aPD‐L1 nanobody (Nb), which can effectively target the immunosuppressive TME and trigger in situ immune checkpoint blockade. The nanoadjuvants responsively release therapeutic components in the acidic TME, enabling the precise tumor location by NIR‐II fluorescence/photoacoustic imaging while initiating NIR‐II photothermal‐ferroptosis therapy. The remarkable NIR‐II photothermal efficiency and elevated glutathione (GSH) depletion further sensitize ferroptosis to induce severe lipid peroxidation, provoking robust immunogenic cell death (ICD) to trigger anti‐tumor immune response. Importantly, the released 2DG markedly inhibits lactate generation through glycolysis obstruction. Decreased lactate efflux remodels the immunosuppressive TME by suppressing M2 macrophage proliferation and downregulating regulatory T cell levels. This work provides a new paradigm for the integration of NIR‐II phototheranostics and lactate metabolism regulation into a single nanoplatform for amplified anti‐tumor immunotherapy combined with ICB therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cancer Centre Institute of Translational Medicine Faculty of Health Sciences University of Macau Macau SAR 999078 China

State Key Laboratory of Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors Institute of Advanced Materials (IAM) Nanjing University of Posts & Telecommunications Nanjing 210023 China

School of Life Sciences Central South University Changsha 410013 China

MoE Frontiers Science Center for Precision Oncology University of Macau Taipa Macau SAR 999078 China

Funding

National Key Research and Development Program of China · Natural Science Foundation of Guangdong Province · Universidade de Macau · National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province

References (38)

Show source-provided references
1. 10.1002/adma.20230674810.1002/adma.202306748 ↗
2. 10.1002/adma.20230719310.1002/adma.202307193 ↗
3. 10.1016/j.biomaterials.2021.12131210.1016/j.biomaterials.2021.121312 ↗
4. 10.1002/adfm.20210043710.1002/adfm.202100437 ↗
5. 10.1016/j.bioactmat.2022.09.00610.1016/j.bioactmat.2022.09.006 ↗
6. 10.1021/acsnano.1c0812010.1021/acsnano.1c08120 ↗
7. 10.1002/anie.20221537210.1002/anie.202215372 ↗
8. 10.1002/anie.20230161710.1002/anie.202301617 ↗
9. 10.1002/adhm.20230209910.1002/adhm.202302099 ↗
10. 10.1016/j.nantod.2023.10183310.1016/j.nantod.2023.101833 ↗
11. 10.1002/adfm.20220846310.1002/adfm.202208463 ↗
12. 10.1002/smll.20210252710.1002/smll.202102527 ↗
13. 10.1002/adfm.20211178410.1002/adfm.202111784 ↗
14. 10.1021/acsnano.3c0004810.1021/acsnano.3c00048 ↗
15. 10.1002/adfm.20220501310.1002/adfm.202205013 ↗
16. 10.1002/anie.20221840710.1002/anie.202218407 ↗
17. 10.1016/j.biomaterials.2022.12177910.1016/j.biomaterials.2022.121779 ↗
18. 10.1002/advs.20210488510.1002/advs.202104885 ↗
19. 10.1038/s41467-020-15730-x10.1038/s41467-020-15730-x ↗
20. 10.1021/acsnano.2c1231910.1021/acsnano.2c12319 ↗
21. 10.1016/j.biomaterials.2023.12215710.1016/j.biomaterials.2023.122157 ↗
22. 10.1021/jacs.1c0975310.1021/jacs.1c09753 ↗
23. 10.1002/adma.20230023210.1002/adma.202300232 ↗
24. 10.1002/adma.20220979910.1002/adma.202209799 ↗
25. 10.1002/agt2.43210.1002/agt2.432 ↗
26. 10.1021/acsnano.0c0707110.1021/acsnano.0c07071 ↗
27. 10.1021/acsnano.3c0242810.1021/acsnano.3c02428 ↗
28. 10.1016/j.biomaterials.2021.12093510.1016/j.biomaterials.2021.120935 ↗
29. 10.1002/ange.20200230610.1002/ange.202002306 ↗
30. 10.1002/ange.20230770610.1002/ange.202307706 ↗
31. 10.1021/acsnano.1c0897810.1021/acsnano.1c08978 ↗
32. 10.1038/nature1349010.1038/nature13490 ↗
33. 10.1002/adma.20190463910.1002/adma.201904639 ↗
34. 10.1021/acsnano.1c0802610.1021/acsnano.1c08026 ↗
35. 10.1038/s41586-020-03045-210.1038/s41586-020-03045-2 ↗
36. 10.1002/adma.20230424610.1002/adma.202304246 ↗
37. 10.3390/pharmaceutics1508202710.3390/pharmaceutics15082027 ↗
38. 10.1002/advs.20190284710.1002/advs.201902847 ↗